How to buy Amylyx Pharmaceuticals stock (Amylyx Pharmaceuticals)

Amylyx Pharmaceuticals is a biotechnology business based in the US. Amylyx Pharmaceuticals shares (AMLX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.33 – an increase of 7.46% over the previous week. Amylyx Pharmaceuticals employs 384 staff and has a trailing 12-month revenue of around $298.8 million.

Our top picks for where to buy Amylyx Pharmaceuticals stock

Buy Amylyx Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Amylyx Pharmaceuticals stock price (NASDAQ: AMLX)

Use our graph to track the performance of AMLX stocks over time.

Amylyx Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$5.33
52-week range	$1.58 - $19.95
50-day moving average more info button	$2.98
200-day moving average more info button	$5.17
Wall St. target price	$4.37
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.46

Is it a good time to buy Amylyx Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Amylyx Pharmaceuticals price performance over time

Historical closes compared with the close of $5.33 from 2024-10-28

1 week (2024-10-22)	17.66%
1 month (2024-09-30)	64.51%
3 months (2024-07-30)	179.06%
6 months (2024-04-30)	194.48%

1 year (2023-10-30)	-66.17%
2 years (2022-10-28)	-85.34%
3 years (2021-10-26)	N/A
5 years (2019-10-26)	N/A

Amylyx Pharmaceuticals financials

Revenue TTM	$298.8 million
Operating margin TTM	7457.09%
Gross profit TTM	$-74,213,000
Return on assets TTM	-28.28%
Return on equity TTM	-51.22%
Profit margin	-55.52%
Book value	$3.84
Market Capitalization more info button	$337.7 million

TTM: trailing 12 months

Amylyx Pharmaceuticals share dividends

We're not expecting Amylyx Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• Sanofi ADR (SNY.US) (3.91% forward annual dividend yield)

Amylyx Pharmaceuticals share price volatility

Over the last 12 months, Amylyx Pharmaceuticals's shares have ranged in value from as little as $1.575 up to $19.949. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amylyx Pharmaceuticals's is -0.553. This would suggest that Amylyx Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Amylyx Pharmaceuticals has bucked the trend.

To put Amylyx Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Cortexyme (CRTX.US): 1.3958
• Alector (ALEC.US): 0.675
• Sanofi ADR (SNY.US): 0.423

Amylyx Pharmaceuticals overview

Amylyx Pharmaceuticals, Inc. , a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

null
What percentage of Amylyx Pharmaceuticals is owned by insiders or institutions?
Currently 14.354% of Amylyx Pharmaceuticals shares are held by insiders and 86.487% by institutions. How many people work for Amylyx Pharmaceuticals?
Latest data suggests 384 work at Amylyx Pharmaceuticals. When does the fiscal year end for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals's fiscal year ends in December. Where is Amylyx Pharmaceuticals based?
Amylyx Pharmaceuticals's address is: 43 Thorndike Street, Cambridge, MA, United States, 02141 What is Amylyx Pharmaceuticals's ISIN number?
Amylyx Pharmaceuticals's international securities identification number is: US0321085088 What is Amylyx Pharmaceuticals's CUSIP number?
Amylyx Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 032108508